Anatomical Resection of Liver MetAstases iN patIents With RAS-mutated Colorectal Cancer
Trial Parameters
Brief Summary
the ARMANI trial will test the hypothesis, if an anatomic resection (AR) improves long-term outcome vs. a non-anatomical resection (NAR) in patients undergoing surgery for RAS-mutated colorectal liver metastasis (CRLM).
Eligibility Criteria
Inclusion Criteria: * Colorectal cancer with RAS mutation (KRAS or NRAS) * Colorectal liver metastases (single or multiple) * Planned R0 resection of liver metastases (and primary tumor, if present) * Anatomical and non-anatomical liver resection technically feasible * Male and female patients, age ≥ 18 years * Written informed consent Exclusion Criteria: * Extrahepatic metastases * Planned staged liver resection (e.g. two-stage hepatectomy) * Diagnosis of another cancer \< 5 years prior to randomization Exceptions: curatively treated in situ cervical cancer, curatively resected non-melanoma skin cancer * Expected lack of compliance * Addiction or other illnesses which do not allow the person concerned to assess the nature and extent of the clinical trial and its possible consequences